Patents Represented by Attorney John P. Cooper & Dunham LLP White
  • Patent number: 6165712
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene encoding a protein of interest, the expression of which gene is associated with the production in cell culture of a protein encoded by the gene, which comprises contacting a cell, which is capable of expressing the gene, with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell in culture, which molecule (a) directly transcriptionally modulates expression of the gene.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 26, 2000
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: J. Gordon Foulkes, Franz E. Leichtfried, Christian Pieler, John R. Stephenson, Casey C. Case
  • Patent number: 6159461
    Abstract: Compositions comprising c-kit ligand, TNF-.alpha., and a hematopoietic factor are useful to promote the expansion of peripheral blood cells or the expansion and differentiation of hematopoietic progenitor cells.
    Type: Grant
    Filed: July 23, 1997
    Date of Patent: December 12, 2000
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Peter Besmer, Jochen Buck, Malcolm A. S. Moore, Karl Nocka
  • Patent number: 6159998
    Abstract: This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: December 12, 2000
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Yoon T. Jeon, Charles Gluchowski
  • Patent number: 6160096
    Abstract: The present invention provides a regenerated collagen fiber exhibiting a draping, luster and feel close to those of a natural protein fiber such as a human hair and capable of application of a permanent wave treatment, and a method of manufacturing the regenerated collagen fiber. The amino group and/or carboxyl group of the regenerated collagen is chemically modified to introduce a mercapto group and/or a disulfide linkage to the regenerated collagen. When subjected to a permanent wave treatment, the regenerated collagen fiber retains the waved shape.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: December 12, 2000
    Assignee: Kaneka Corporation
    Inventors: Shinichi Sakashita, Mamoru Tsugawa, Masaoki Goto, Kunihiko Matsumura, Norio Hirokawa
  • Patent number: 6159990
    Abstract: This invention is directed to oxazolidinone compounds which are selective antagonists for human .alpha..sub.1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the .alpha..sub.1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 17, 1998
    Date of Patent: December 12, 2000
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Bharat Lagu, T.G. Murali Dhar, Dhanapalan Nagarathnam, Yoon T. Jeon, Mohammad R. Marzabadi, Wai C. Wong, Charles Gluchowski
  • Patent number: 6159751
    Abstract: This invention provides a method for preparing a hybridoma cell line which produces a monoclonal antibody which specifically recognizes and binds to a tumor associated antigen which comprises: (a) cotransfecting a CREF-Trans 6 cell line with DNA isolated from a neoplastic, human cell and a plasmid which encodes a selectable or identifiable trait; (b) selecting transfected cells which express the selectable or identifiable trait; (c) recovering the cells so selected in step (b); (d) injecting the cells so recovered in step (c) into a suitable marine host; (e) maintaining the resulting first murine host for a period of time effective to induce the cells injected in step (d) to form a tumor in the murine host; (f) isolating the tumor formed in step (e); (g) obtaining tumor cells from the isolated tumor in step (f); (h) coating the tumor cells obtained in step (9) with an antiserum generated against the CREF Trans-6 cell line (i) injecting the antiserum-coated cells from step (h) into a plurality of suitable seco
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 12, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Paul B. Fisher
  • Patent number: 6156316
    Abstract: Fusion-point spanning peptides, for example BCR-ABL fusion breakpoint peptides associated with chronic myelogenous leukemia (CML), bind major histompatibility complex molecules, such as HLA class I molecules, and induce cytotoxic T cell proliferation. The breakpoint peptides can be used as vaccines.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: December 5, 2000
    Assignees: Sloan-Kettering Institute for Cancer Research, Cytel Corporation
    Inventors: David A. Scheinberg, Alessandro Sette, Monica Bocchia
  • Patent number: 6155013
    Abstract: A floorboard for clean rooms is disclosed. The floorboard has a support unit (110) and a tile unit (120). In the support unit (110), a plate part (111) has a plurality of engaging holes (114) on its upper surface. A support part (112) is vertically and integrally formed along the edge of the lower surface of said plate part. A plurality of reinforcing ribs (113) linearly, regularly and integrally extend on the lower surface of the plate part in a way such that the ribs are integrated with both the plate part and the support part. In the tile unit (120), a cover part (121) engages with the upper surface of the plate part. A plurality of engaging projections are (122) formed on the lower surface of the cover part at positions corresponding to the engaging holes (114) of the support unit, thus engaging with the engaging holes of the support unit. Each of the engaging projections has a ventilation hole (123) at its central portion.FIG. 4 shows the most relevant embodiment.
    Type: Grant
    Filed: February 8, 1999
    Date of Patent: December 5, 2000
    Assignee: Hae Kwang Co., Ltd.
    Inventor: Chae-Won Kim
  • Patent number: 6156577
    Abstract: A method of measuring an amount of a polyphenol compound in a liquid sample containing at least one polyphenol compound comprises a step of separating the liquid sample into each component, a step of adding at least one reagent capable of specifically reacting with the polyphenol compound to emit light, into the components separated in the separating step, thereby to perform a reaction, and a step of detecting the light emitted by the reaction, wherein the separation in the separating step is conducted by a liquid chromatography and the reagent used for the reaction is the combination of an oxidizing agent of the polyphenol compound, a heme compound and a hydrogen acceptor. A device suitable for performing the above method is also disclosed.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: December 5, 2000
    Assignee: Tohoku Electronic Industrial Co., Ltd.
    Inventors: Teruo Miyazawa, Kiyotaka Nakagawa, Rie Yamada
  • Patent number: 6156315
    Abstract: This invention also provides a method of treating atherosclerosis in a subject, comprising administering to the subject an effective amount of a substance capable of binding to the amino-terminal region of apolipoprotein B, thereby treating the atherosclerosis. This invention also provides a method for inhibiting the binding of low density lipoprotein to blood vessel matrix in a subject, comprising administering to the subject an effective amount of a substance capable of competing with the amino-terminal region of apolipoprotein B for binding to blood vessel matrix, thereby inhibiting the binding of low density lipoprotein to blood vessel matrix. This invention also provides a method for identifying a compound capable of ameliorating atherosclerosis. Additionally, this invention provides a kit for inhibiting the binding of low density lipoprotein to blood vessel matrix, wherein the kit comprises a substance capable of binding to the amino-terminal region of apolipoprotein B.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: December 5, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Ira J. Goldberg, Sivaram Pillarisetti
  • Patent number: 6150093
    Abstract: This invention provides an isolated DNA molecule which is at least 30 nucleotides in length and which uniquely defines a herpesvirus associated with Kaposi's sarcoma. This invention provides an isolated herpesvirus associated with Kaposi's sarcoma. This invention provides an antibody specific to the peptide. Antisense and triplex oligonucleotide molecules are also provided. This invention provides a method of vaccinating a subject for KS, prophylaxis diagnosing or treating a subject with KS and detecting expression of a DNA virus associated with Kaposi's sarcoma in a cell.
    Type: Grant
    Filed: February 18, 1997
    Date of Patent: November 21, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Yuan Chang, Patrick S. Moore
  • Patent number: 6146877
    Abstract: This invention provides an isolated nucleic acid molecule encoding a Progression Elevated Gene-3 protein. This invention also provides isolated nucleic acid molecule encoding a human Progression Elevated Gene-3 protein. This invention provides a nucleic acid molecule of at least 12 nucleotides capable of specifically recognizing a nucleic acid molecule encoding a Progression Elevated Gene-3 protein. This invention provides a method of detecting expression of the Progression Elevated Gene-3 in a sample. This invention provides an isolated nucleic acid molecule encoding a Progression Elevated Gene-3 protein operatively linked to a regulatory element. This invention provides a host vector system for the production of a polypeptide having the biological activity of a Progression Elevated Gene-3 protein. This invention also provides a purified Progression Elevated Gene-3 protein and a fragment thereof. This invention provides an antibody capable of specifically binding to a Progression Elevated Gene-3 protein.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: November 14, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Paul B. Fisher
  • Patent number: 6146826
    Abstract: This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein. This invention also provides living organisms which comprise the above-described cell. This invention also provides a method for selecting cells expressing a protein of interest which comprises: a) introducing into the cells a DNAI molecule having DNA sequence encoding the protein of interest and DNAII molecule having DNA sequence encoding a green fluorescent protein; b) culturing the introduced cells under conditions permitting expression of the green fluorescent protein and the protein of interest; and c) selecting the cultured cells which express green fluorescent protein, thereby selecting cells expressing the protein of interest. Finally, this invention provides various uses of a green fluorescent protein.
    Type: Grant
    Filed: June 18, 1996
    Date of Patent: November 14, 2000
    Assignees: The Trustees of Columbia University in the City of New York, Woods Hole Oceanographic Institution
    Inventors: Martin Chalfie, Douglas Prasher
  • Patent number: 6147616
    Abstract: The present invention provides a digital automatic power interruption and re-supply relay for performing detection and comparing operation to inform a state of an accident with voice and numerals and automatically operating a connected relay to interrupt power when there occur abnormal changes such as interruption of electric power, open-phase, anomalous voltage, unbalanced voltage, negative-phase, overcurrent, and electric leakage in a power transmit and supply line of high and low voltage or special high voltage and high (low) voltage and, after compensating for the accident, for automatically re-supplying the power.
    Type: Grant
    Filed: March 23, 1999
    Date of Patent: November 14, 2000
    Inventor: Myung Dong Kim
  • Patent number: 6136779
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.
    Type: Grant
    Filed: January 6, 1997
    Date of Patent: October 24, 2000
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson
  • Patent number: 6136570
    Abstract: The present invention relates to methods for producing RNA virus cDNA, methods for producing viable, RNA virus and viable, RNA virus produced by those methods. The invention also related to a novel RNA virus cDNA, recombinant DNA molecules containing that cDNA and hosts transformed with those recombinant cDNA molecules. This invention further related to novel methods for screening for variants of a strain 3 poliovirus. This invention also related to methods for increasing the attenuation of a strain poliovirus.This invention provides a vaccine useful for immunizing a subject, for example a human, against infectious poliovirus, wherein the vaccine comprises an effective amount of an RNA virus, produced by transforming a suitable host cell with a recombinant nucleic acid sequence which encodes for the virus: culturing the host cell under conditions which permit the production of virus: and isolating the virus so produced, effective to immunize the subject, and a suitable carrier.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 24, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Vincent Racaniello, Joanne Marie Tatem, Carolyn L. Weeks-Levy
  • Patent number: 6136582
    Abstract: This invention provides a polypeptide capable of polymerizing i) deoxyribonucleotides; ii) ribonucleotides; or iii) one or more deoxyribonucleotides and one or more ribonucleotides. This invention further provides a purified Moloney murine leukemia virus reverse transcriptase, wherein an amino acid corresponding to position 155 of a wild type Moloney murine leukemia virus reverse transcriptase is a valine. This invention also provides a method of polymerizing a nucleic acid molecule comprising one or more deoxyribonucleotides and one or more ribonucleotides comprising: contacting a polypeptide capable of polymerizing i) deoxyribonucleotides; ii) ribonucleotides; or iii) one or more deoxyribonucleotides and one or more ribonucleotides with deoxyribonucleotides and ribonucleotides under conditions permitting incorporation of deoxyribonucleotides and ribonucleotides into a nucleic acid molecule.
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: October 24, 2000
    Assignee: The Trustees of Columbia University in the City
    Inventors: Guangxia Gao, Stephen P. Goff
  • Patent number: 6136318
    Abstract: This invention provides a recombinant fowlpox virus comprising a foreign DNA sequence inserted into the fowlpox virus genomic DNA, wherein the foreign DNA sequence is inserted within a 3.5 kB EcoRI fragment of the fowlpox virus genomic DNA and is capable of being expressed in a fowlpox virus infected host cell. The invention further provides homology vectors, vaccines and methods of immunization.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 24, 2000
    Inventors: Mark D. Cochran, David E. Junker
  • Patent number: 6127131
    Abstract: This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammamlian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic said molecule which encodes a human glycine transporter, pharmaceutical compounds r
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: October 3, 2000
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, Laurence A. Borden, Theresa Branchek, Paul R. Hartig, Richard L. Weinshank
  • Patent number: 6127163
    Abstract: The present invention relates to a recombinant swinepox virus capable of replication comprising foreign DNA inserted into a site in the swinepox viral DNA which is not essential for replication of the swinepox virus.
    Type: Grant
    Filed: January 19, 1996
    Date of Patent: October 3, 2000
    Assignee: Syntro Corporation
    Inventors: Mark D. Cochran, David E. Junker